● neutral
Impact
PhaseNot stated
Time to marketNot stated
KPI-014 Updated Nov 12
What to watch
KPI-014 is an early preclinical program at a company that recently suffered a clinical failure (KPI-012 Phase 2b miss in September 2025), has a market cap around $3M, and is pivoting to an AI platform business model. Watch for any mention of KPI-014 in future corporate updates, but the program appears dormant or deprioritized given the company's financial constraints and strategic shift.
Bull case
- KPI-014 targets inherited retinal degenerative diseases (retinitis pigmentosa, Stargardt disease), areas with significant unmet need and no approved therapies for many patients.
- The MSC-S platform is a novel biologic approach that could differentiate from gene therapy competitors if preclinical data prove promising.
- KALA BIO has dramatically reduced its cash burn (Q3 2026 net loss of ~$0.8M vs $7.6M in Q3 2025), extending its runway to potentially advance early-stage programs.
Bear case
- KPI-014 is preclinical only with no clinical trials initiated, no IND filed, and no hard catalyst in the next ~12 months.
- KALA BIO's lead candidate KPI-012 failed its Phase 2b CHASE study in September 2025, causing an 88% stock crash and raising questions about the MSC-S platform's therapeutic potential.
- The company is pivoting to an AI infrastructure platform business model, suggesting KPI-014 and the broader biologics pipeline may be deprioritized.